title: Efficacy of glimepiride in patients with poorly controlled insulin-treated type 2 diabetes mellitus.
abstract: We retrospectively investigated the effects of adding glimepiride in patients with type 2 diabetes showing suboptimal control by insulin therapy. Of 63 patients with poorly controlled insulin-treated type 2 diabetes (baseline HbA1c, 8.4 +/- 0.6%), 32 were treated with insulin alone and 31 were given glimepiride in addition to insulin. HbA1c values, daily insulin dose, body weight, blood pressure, plasma lipid concentrations, and the number of hypoglycemic events were recorded at weeks 0, 12, 24, 36, 48, 60, and 72. HbA1c decreased by 1.1%, from 8.5 +/- 0.6% to 7.4 +/- 0.8% (P<0.0001) in patients treated with insulin plus glimepiride at 12 weeks, and improved glycemic control continued throughout the study. Required insulin dose was reduced significantly in patients treated with insulin plus glimepiride (from 29.4 +/- 14.5 to 22.3 +/- 12.1 units/day, P = 0.0187). Body weight increased significantly in patients treated with insulin plus glimepiride (from 57.0 +/- 8.7 to 59.5 +/- 9.2 kg, P = 0.0232). Adding glimepiride showed little effect on blood pressure, plasma total cholesterol, triglyceride, or HDL-cholesterol. Serum C peptide concentrations increased significantly in patients treated with insulin plus glimepiride (from 1.01 +/- 0.71 to 1.28 +/- 0.65 ng/ml, P = 0.0367). The number of hypoglycemic events did not differ between groups. Adding glimepiride to insulin therapy resulted in sustained improvement of glycemic control in patients with poorly controlled type 2 diabetes.
authors.affiliation: Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Japan.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Ose
authors.forename: Michiaki
authors.initials: M
authors.lastname: Fukui
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Kitagawa
authors.forename: Chizuko
authors.initials: C
authors.lastname: Hirata
authors.forename: Naoko
authors.initials: N
authors.lastname: Ichio
authors.forename: Mayuko
authors.initials: M
authors.lastname: Kadono
authors.forename: Shin-ichi
authors.initials: S
authors.lastname: Mogami
authors.forename: Masayoshi
authors.initials: M
authors.lastname: Onishi
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Ichida
authors.forename: Toshiki
authors.initials: T
authors.lastname: Nakajima
authors.forename: Goji
authors.initials: G
authors.lastname: Hasegawa
authors.forename: Toshikazu
authors.initials: T
authors.lastname: Yoshikawa
authors.forename: Naoto
authors.initials: N
authors.lastname: Nakamura
mesh_terms: D000368:Aged; D001786:Blood Glucose / Q000378:metabolism; D002096:C-Peptide / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007328:Insulin / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*
chemical_list: D001786:Blood Glucose; D002096:C-Peptide; D006442:Glycated Hemoglobin; D007328:Insulin; D013453:Sulfonylurea Compounds; C057619:glimepiride